Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
EZZ Life Science Holdings Ltd. ( (AU:EZZ) ) has issued an update.
EZZ Life Science Holdings Limited reported strong financial performance for FY25, with revenue reaching $66.9 million and a significant presence in Southeast Asia. The company achieved strategic milestones, including entering the U.S. market with FDA-registered products and expanding its Southeast Asian footprint through a distribution agreement. EZZ also launched 15 new products and enhanced its domestic retail presence. With a robust balance sheet and expanding international reach, EZZ is poised for sustained growth and enhanced shareholder value in FY26.
The most recent analyst rating on (AU:EZZ) stock is a Hold with a A$2.50 price target. To see the full list of analyst forecasts on EZZ Life Science Holdings Ltd. stock, see the AU:EZZ Stock Forecast page.
More about EZZ Life Science Holdings Ltd.
EZZ Life Science Holdings Limited is a life science company focused on improving human health and quality of life through science-backed innovation. The company operates a global omnichannel platform with strong positions in Australia, New Zealand, and China, and is expanding into key international markets including the United States and Southeast Asia. EZZ connects consumers to health solutions via digital engagement, retail partnerships, and continuous product development.
Average Trading Volume: 73,117
Technical Sentiment Signal: Buy
Current Market Cap: A$109M
See more insights into EZZ stock on TipRanks’ Stock Analysis page.